Biosimilar success depends on analytical evidence. Regulators expect precise, defensible bioanalytical data that clearly demonstrate similarity to the reference product.
QPS has deep experience with FDA, EMA and WHO guidelines and expectations, and can deliver harmonized, inspection‑ready data packages that accelerate biosimilar approval worldwide.
QPS Global Regulatory Affairs (GRA) collaborates with pharma, biotech, and medical device companies to build tailored research strategies that speed a compliant path from discovery through global commercialization and full lifecycle support.
QPS can help you navigate the complex GRA framework, ensuring compliant, efficient submissions that accelerate global market access.
Pancreatic cancer is an aggressive, highly lethal malignancy, with some of the highest mortality rates of all major cancers. In fact, per the Pancreatic…
We use your email address exclusively for sending QPS newsletters with a special e-mail program. If you no longer wish to receive any mailings, simply use the "unsubscribe" link at the bottom. If you don't unsubscribe, we assume that this consent also applies to the system of the GDPR. (Data protection notice: According to Art. 7 GDPR, the consent can of course also be withdrawn at any time after May 25, 2018.)
QPS Holdings, LLC | Three Innovation Way Suite 240 | Newark , DE 19711 US
